Copyright © Inderes 2011 - present. All rights reserved.
Log in to receive notifications.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Diamyd Medical

8.4

 

SEK

 

+8.11 %

Less than 1K followers

DMYD B

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus
+8.11%
+2.68%
-51.48%
-48.35%
-35.57%
-28.65%
-44.07%
-56.47%
+181.47%

Diamyd Medical is a diabetes company. The company develops the diabetes vaccine Diamyd® with the active ingredient GAD, which has the potential to become a key piece of the puzzle of a future solution to prevent, treat or cure type 1 diabetes and other forms of diabetes. Diamyd Medical has independently pursued the development of the diabetes vaccine Diamyd® to global Phase III trial.

Read more
Market cap
1.09B SEK
Turnover
4.18M SEK
Revenue
130K
EBIT %
-112,746.15 %
P/E
-
Dividend yield-%
-
Financial calendar
25/6
2025

Interim report Q3'25

8/10
2025

Annual report '25

All
Research
Webcasts
Press releases
3rd party
ShowingAll content types
Regulatory press releaseyesterday

Diamyd Medical AB: Sista teckningsdag i Diamyd Medicals företrädesemission

Diamyd Medical
Regulatory press releaseyesterday

Diamyd Medical AB: Last day of the subscription period in Diamyd Medicals rights issue

Diamyd Medical
Regulatory press releaseyesterday

Diamyd Medical AB: Europa beviljar Diamyd Medical patent för precisionsmedicin med insulinantigen vid autoimmun diabetes

Diamyd Medical

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press releaseyesterday

Diamyd Medical AB: Europe to grant precision medicine patent to Diamyd Medical for insulin antigen treatment in autoimmune diabetes

Diamyd Medical
Regulatory press release4/25/2025, 12:00 PM

Diamyd Medical AB: Diamyd Medicals fas 3-studie i typ 1-diabetes har passerat den näst sista säkerhetsgranskningen inför resultatavläsningen i mars 2026

Diamyd Medical
Regulatory press release4/25/2025, 12:00 PM

Diamyd Medical AB: Diamyd Medical's pivotal Phase 3 Type 1 Diabetes trial clears second-to-last safety review ahead of early readout in March 2026

Diamyd Medical
Press release4/24/2025, 6:30 AM

Carnegie Access: Diamyd Medical: Intervju - Statusuppdatering

Diamyd Medical
Regulatory press release4/22/2025, 12:05 PM

Diamyd Medical AB: Aktieägare i Diamyd Medical, däribland styrelseordföranden, har lämnat ytterligare teckningsförbindelser i pågående företrädesemission

Diamyd Medical
Regulatory press release4/22/2025, 12:05 PM

Diamyd Medical AB: Shareholders in Diamyd Medical, including the Chairman of the Board, have provided additional subscription commitments in the ongoing rights issue

Diamyd Medical
Regulatory press release4/21/2025, 9:00 AM

Diamyd Medical AB: Diamyd Medical lyfter fram potentialen för prevention, vuxendebut av typ 1-diabetes och kommande fas 3-avläsning

Diamyd Medical
Regulatory press release4/21/2025, 9:00 AM

Diamyd Medical AB: Diamyd Medical highlights opportunity in Type 1 Diabetes prevention, adult-onset market, and upcoming Phase 3 readout

Diamyd Medical
Press release4/17/2025, 8:15 AM

Impala Nordic: Diamyd Medical - Investeringscase

Diamyd Medical
Regulatory press release4/17/2025, 7:30 AM

Diamyd Medical AB: The prevention trial DiaPrecise with Diamyd® clears first safety milestone

Diamyd Medical
Regulatory press release4/17/2025, 7:30 AM

Diamyd Medical AB: Preventionsstudien DiaPrecise med Diamyd® passerar första säkerhetsmilstolpen

Diamyd Medical
Regulatory press release4/15/2025, 3:45 PM

Diamyd Medical AB: Australia grants Diamyd Medical patent for novel antigen combination in autoimmune diabetes treatment

Diamyd Medical
Regulatory press release4/15/2025, 3:45 PM

Diamyd Medical AB: Australien beviljar Diamyd Medical patent för ny antigenkombination vid behandling av autoimmun diabetes

Diamyd Medical
Regulatory press release4/14/2025, 11:10 AM

Diamyd Medical AB: Diamyd Medical offentliggör prospekt avseende företrädesemissionen

Diamyd Medical
Regulatory press release4/14/2025, 11:10 AM

Diamyd Medical AB: Diamyd Medical publishes prospectus with regards to the rights issue

Diamyd Medical
Press release4/9/2025, 5:07 PM

Carnegie Access: Diamyd Medical: Steady progression towards major inflection point – Q2 review

Diamyd Medical
Regulatory press release4/9/2025, 6:15 AM

Diamyd Medical AB: Quarterly Report 2 24/25

Diamyd Medical
Forum discussions
Diamyd Medical är ett bolag inne i en händelserik period. Detta är Diamyd i korta drag hämtat från deras hemsida: Med huvudprodukten Diamyd har man tagit steg där Diamyd är ett intressant läkemedel som verkar ha potential att förbättra blodsockerkontrollen och minska komplikationerna...
4/12/2024, 9:25 AM
by Jesper Hagman
5
Diamyd meddelade igår det preliminära utfallet i företrädesemission vilket indikerar att cirka 4,2 miljoner units, motsvarande cirka 44 procent av företrädesemissionen tecknats med stöd av uniträtter. Inderes Diamyd Medical AB: Diamyd Medical offentliggör preliminärt utfall i bolagets...
4/17/2024, 6:25 AM
by Jesper Hagman
2
Read more on our forum
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Privacy preferences

Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.